EMA to review Samsung Bioepis and Biogen biosimilar ranibizumab
The European Medicines Agency will now review the market authorisation application for this biosimilar anti-VEGF (vascular endothelial growth factor) for retinal vascular disorders, with Lucentis as the reference product.
Source:
Biospace Inc.